JNJ Johnson & Johnson

Price (delayed)

$140.97

Market cap

$371.4B

P/E Ratio

21.65

Dividend/share

$3.86

EPS

$6.51

Enterprise value

$383.45B

Business Summary

Sector: Healthcare
Industry: Drug Manufacturers - General
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Highlights

JNJ's price to earnings (P/E) is 70% lower than its 5-year quarterly average of 71.2 and 5% lower than its last 4 quarters average of 22.8
The EPS has grown by 19% YoY and by 14% from the previous quarter

Key stats

Shares outstanding
2.63B
Market cap
$371.4B
Enterprise value
$383.45B
EBIT
$19.66B
EBITDA
$26.65B
Price to earnings (P/E)
21.65
Price to book (P/B)
6.05
Price to sales (P/S)
4.49
EV/EBIT
19.51
EV/EBITDA
14.39
Net debt/EBITDA
0.45
EV/Sales
4.64
EBITDA margin
32.2%
Gross margin
66.2%
Net margin
20.7%
Operating margin
25.6%
Return on assets
11%
Return on equity
28.6%
Return on invested capital
37.2%
Return on capital employed
16.2%
Return on sales
23.8%
Debt to equity
0.45
Free cash flow
$19.76B
Free cash flow per share
$7.5
Book value per share
$23.29
Revenue per share
$31.41
TBVPS
$28.18
Current ratio
1.31
Quick ratio
0.54
Working capital
$10.54B
Dividend yield
2.74%
DPS
$3.86
Payout ratio
59.3%

JNJ stock price

Financial performance

Johnson & Johnson's net income has increased by 17% YoY and by 14% QoQ
Johnson & Johnson's net margin has increased by 15% YoY and by 13% from the previous quarter
The operating income rose by 15% year-on-year and by 7% since the previous quarter
Johnson & Johnson's operating margin has increased by 13% YoY and by 6% from the previous quarter

Valuation

Price to earnings (P/E)
Current price to earnings (P/E):
21.65
JNJ's price to earnings (P/E) is 70% lower than its 5-year quarterly average of 71.2 and 5% lower than its last 4 quarters average of 22.8
The EPS has grown by 19% YoY and by 14% from the previous quarter
Price to book (P/B)
Current price to book (P/B):
6.05
JNJ's price to book (P/B) is 16% more than its 5-year quarterly average of 5.2 and 2.5% more than its last 4 quarters average of 5.9
JNJ's equity is up by 4% year-on-year and by 3.1% since the previous quarter
Price to sales (P/S)
Current price to sales (P/S):
4.49
The price to sales (P/S) is 4.4% more than the last 4 quarters average of 4.3 and 2% more than the 5-year quarterly average of 4.4

Efficiency

Johnson & Johnson's return on invested capital has increased by 25% YoY and by 14% QoQ
The company's return on equity rose by 20% YoY and by 12% QoQ
The return on assets has increased by 15% year-on-year and by 12% since the previous quarter
The ROS has grown by 11% from the previous quarter and by 9% YoY

Dividends

DPS
$3.86
Dividend yield
2.74%
Payout ratio
59.3%

Recent dividends

Financial health

Assets vs liabilities
JNJ's total assets is 65% greater than its total liabilities
JNJ's current ratio is down by 9% year-on-year but it is up by 4% since the previous quarter
Johnson & Johnson's total liabilities has decreased by 4.6% from the previous quarter but it has increased by 2.9% YoY
Debt vs equity
Johnson & Johnson's debt is 55% less than its equity
The company's debt to equity fell by 10% YoY and by 4.3% QoQ
JNJ's equity is up by 4% year-on-year and by 3.1% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.